Drug Trial Radar · NCT01404312
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,000
Actual
Start
May 23, 2012
Primary completion
Nov 14, 2017
Study completion Nov 14, 2017
Sponsor
- Sponsor type
- NIH
- First posted
- Jul 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of rifapentine (RPT) plus INH versus a standard 9-month regimen of INH in HIV-infected people who are at risk of developing active TB.
Conditions
- Tuberculosis
- HIV Infections
Interventions
Rifapentine (RPT)Drug
RPT dosing was be based on participants' weight: Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets). Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets). Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets).
Isoniazid (INH)Drug
Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
Pyridoxine (Vitamin B6)Dietary supplement
Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines. Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH. Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown CauseTime frame: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
Locations
45 sites in 10 countries. Site status is shown where the registry gives one.
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program
La Jolla, California
University of Southern California CRS
Los Angeles, California
UCSD Antiviral Research Center CRS
San Diego, California
Ucsf Hiv/Aids Crs
San Francisco, California
Harbor-UCLA CRS
Torrance, California
University of Colorado Hospital CRS
Aurora, Colorado
Denver Public Health CRS
Denver, Colorado
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
Miami, Florida
Northwestern University CRS
Chicago, Illinois
Boston Medical Center CRS
Boston, Massachusetts
Henry Ford Hosp. CRS
Detroit, Michigan
Cooper Univ. Hosp. CRS
Camden, New Jersey
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey
Nyu Ny Nichd Crs
New York, New York
Columbia P&S CRS
New York, New York
Bronx-Lebanon Hospital Center NICHD CRS
The Bronx, New York
Chapel Hill CRS
Chapel Hill, North Carolina
Duke University Medical Center CRS
Durham, North Carolina
Trinity Health and Wellness Center CRS
Dallas, Texas
Houston AIDS Research Team CRS
Houston, Texas
University of Washington AIDS CRS
Seattle, Washington
Gaborone CRS
Gaborone, Botswana
Molepolole CRS
Gaborone, Botswana
Hospital Federal dos Servidores do Estado NICHD CRS
Rio de Janeiro, Brazil
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, Brazil
Hosp. Geral De Nova Igaucu Brazil NICHD CRS
Rio de Janeiro, Brazil
Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS
São Paulo, Brazil
Hospital Nossa Senhora da Conceicao CRS
Porto Alegre, Rio Grande do Sul, Brazil
Univ. of Sao Paulo Brazil NICHD CRS
São Paulo, São Paulo, Brazil
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, Haiti
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
Port-au-Prince, Haiti
Moi University Clinical Research Center (MUCRC) CRS
Eldoret, Kenya
Kisumu Crs
Kisumu, Nyanza, Kenya
Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS
Kericho, Rift Valley, Kenya
Blantyre CRS
Blantyre, Malawi
Malawi CRS
Lilongwe, Central Region, Malawi
Barranco CRS
Lima, Peru
San Miguel CRS
Lima, Peru
Soweto ACTG CRS
Johannesburg, Gauteng, South Africa
Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Johannesburg, Gauteng, South Africa
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.